Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;104(7):1322-1323.
doi: 10.1097/TP.0000000000002979.

A Cautionary Tale: Declining Renal Function Following Acute Rejection Post Conversion From Calcineurin Inhibitor to Belatacept in HLA-sensitized Individuals in the First Posttransplant Year

Gemma D Banham  1
Affiliations
Comment

A Cautionary Tale: Declining Renal Function Following Acute Rejection Post Conversion From Calcineurin Inhibitor to Belatacept in HLA-sensitized Individuals in the First Posttransplant Year

Gemma D Banham. Transplantation. 2020 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Durrbach A, Pestana JM, Florman S, et al. Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant. 2016; 16:3192–3201
    1. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016; 374:333–343
    1. Leibler C, Matignon M, Moktefi A, et al. Belatacept in renal transplant recipient with mild immunologic risk factor: a pilot prospective study (BELACOR). Am J Transplant. 2019; 19:894–906
    1. Grinyó JM, Del Carmen Rial M, Alberu J, et al. Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial. Am J Kidney Dis. 2017; 69:587–594
    1. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011; 6:430–439

LinkOut - more resources